Skip to main content

Nulibry Side Effects

Generic name: fosdenopterin

Medically reviewed by Drugs.com. Last updated on Aug 20, 2023.

Note: This document contains side effect information about fosdenopterin. Some dosage forms listed on this page may not apply to the brand name Nulibry.

Applies to fosdenopterin: intravenous powder for solution.

Serious side effects of Nulibry

Along with its needed effects, fosdenopterin (the active ingredient contained in Nulibry) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking fosdenopterin:

More common

Less common

Other side effects of Nulibry

Some side effects of fosdenopterin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to fosdenopterin: intravenous powder for injection.

General

Adverse reactions were assessed in 9 patients; the most reported reaction was catheter-related complications which were reported in 8 patients. Phototoxicity was reported in animals and patients are advised to avoid exposure to sunlight and use sun protection when that is not possible.[Ref]

Local

Very common (10% or more): Catheter-related complications (89%)

Catheter-related complications included complication associated with device, catheter site abscess, catheter site discharge, catheter site extravasation, catheter site pain, catheter site infection, catheter site inflammation, device dislocation, device leakage, device occlusion, and vascular device infection. Catheter-related complications occurred in 8 of 9 patients evaluated for adverse-reactions.

Respiratory

Very common (10% or more): Pneumonia (44%), coughing/sneezing (44%), upper viral respiratory infection (33%), lower respiratory tract infection (22%), viral tonsillitis (22%)

Nervous system

Very common (10% or more): Seizure (22%)

Dermatologic

Very common (10% or more): Rash maculo-papular (22%)

Frequency not reported: fungal skin infection, eczema

Gastrointestinal

Very common (10% or more): Vomiting (44%), gastroenteritis (33%), diarrhea (33%), abdominal pain (22%), oropharyngeal pain (22%)

Frequency not reported: Fatal necrotizing enterocolitis, oral candidiasis

One patient dies of necrotizing enterocolitis.

Immunologic

Very common (10% or more): Viral infection (56%), bacteremia (33%), influenza (22%)

Frequency not reported: Sepsis, varicella

Ocular

Very common (10% or more): Eye swelling (22%)

Psychiatric

Very common (10% or more): Agitation (22%)

Hematologic

Very common (10% or more): Anemia (22%)

Other

Very common (10% or more): Pyrexia (78%), otitis media (44%)

References

1. Product Information. Nulibry (fosdenopterin). Origin Biosciences Inc. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.